Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:13 PM
Ignite Modification Date:
2025-12-24 @ 7:13 PM
NCT ID:
NCT05260203
Eligibility Criteria:
Inclusion Criteria:
* Patients who understand and voluntarily sign an informed consent form (ICF) prior to any study related procedures being conducted;
* Patients who are ≥ 18 years old;
* Patients who are diagnosed with a onco-hematologic disease, namely: Symptomatic Multiple Myeloma, Solitary Plasmocytoma, Amyloidosis, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Hodgkin Lymphoma, B cells non-Hodgkin Lymphoma, T cells non-Hodgkin Lymphoma, Acute myeloid Leukemia, Myelodysplasia, Chronic Myeloproliferative Disorder;
* Patients who receive a standard of care therapy for their disease, independently from the route of administration;
* Patients in their first or subsequent line of therapy;
* Patients at the beginning of the treatment, or during therapy;
* Life expectancy \> 6 months.
Exclusion Criteria:
* Patients treated with radiotherapy only;
* Presence of clinical conditions that will impair the adherence to the treatment (ie, concomitant tumor on treatment, severe neurologic disease, drug or alcohol abuse etc.);
* Patient unable to use a smartphone and/or a computer (ie blindness, inability to use a smartphone or a computer etc.);
* Major psychopathology or cognitive impairment likely in the judgment of the research staff to interfere with the participation or completion of the protocol;
* Patient enrolled in another clinical trial.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05260203
Study Brief:
Protocol Section:
NCT05260203